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Abstract
Background: Combination of oncolytic vaccinia virus therapy with conventional chemotherapy has shown
promise for tumor therapy. However, side effects of chemotherapy including thrombocytopenia, still remain
problematic.
Methods: Here, we describe a novel approach to optimize combination therapy of oncolytic virus and
chemotherapy utilizing virus-encoding hyper-IL-6, GLV-1h90, to reduce chemotherapy-associated side effects.
Results: We showed that the hyper-IL-6 cytokine was successfully produced by GLV-1h90 and was functional both
in cell culture as well as in tumor-bearing animals, in which the cytokine-producing vaccinia virus strain was well
tolerated. When combined with the chemotherapeutic mitomycin C, the anti-tumor effect of the oncolytic
virotherapy was significantly enhanced. Moreover, hyper-IL-6 expression greatly reduced the time interval during
which the mice suffered from chemotherapy-induced thrombocytopenia.
Conclusion: Therefore, future clinical application would benefit from careful investigation of additional cytokine
treatment to reduce chemotherapy-induced side effects.
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Background
Interleukin-6 (IL-6) is one of the best characterized cyto-
kines and much is known about its pleiotropic behavior.
As described by many groups, IL-6 is produced by both
lymphoid and nonlymphoid cells, such as T cells, B cells,
monocytes, endothelial cells, fibroblasts and many tumor
cell types [1]. It is also therefore involved in many biologi-
cal processes including upregulation of acute phase pro-
teins during inflammation [2], immune regulation and
hematopoiesis [3] as well as hemostasis which includes
platelet formation [4]. Furthermore, IL-6 has been shown
to play a pathogenic role in the development and progres-
sion of several tumor types [5]. In contrast to this, IL-6
has been shown to possess anti-tumor effects as in the
example of treatment of B16 melanoma [6] or small cell
lung carcinoma [7]. In both cases, the growth or prolifera-
tion inhibition could only be detected after addition of
soluble IL-6 receptor (sIL-6-R) in cell culture systems,
indicating that the pleiotropic effects of IL-6 may be due
to differing mechanisms in signal transduction. Two dif-
ferent forms of the IL-6 receptor have been characterized
which orchestrate the signaling pathways of the cytokine.
IL-6 binds to either a specific receptor on the cell surface
(mIL-6-R) of hepatocytes, monocytes/macrophages and
leukocytes [8] or to the soluble, circulating sIL-6-R version
generated by alternative splicing or by shedding of the
mIL-6-R. The latter kind of signal transduction is named
IL-6 trans-signaling (IL-6TS) which can potentiate the sig-
nal transduced by mIL-6R and also extend the range of
target cells [9]. In both cases, the IL-6/(s/m)IL-6-R
* Correspondence: aaszalay@genelux.com
1Department of Biochemistry, University of Würzburg, 97074 Würzburg,
Germany
Full list of author information is available at the end of the article
Sturm et al. Journal of Translational Medicine 2012, 10:9
http://www.translational-medicine.com/content/10/1/9
© 2012 Sturm et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
complex binds to the glycoprotein gp130 which then
forms homodimers [10], leading to activation of the Ras/
MAPK- and the JAK/STAT pathway [11]. The JAK/STAT
pathway in turn results in phosphorylation of STAT3, fol-
lowed by dimerization and accumulation in the cell
nucleus where phosphorylated STAT3 dimers act as tran-
scription factors [12].
To further characterize the IL-6TS, Rose-John et al.
(1996) constructed a fusion protein, named hyper-IL-6, in
which human IL-6 is covalently linked to the human sIL-
6R [13]. The hyper-IL-6 designer cytokine activates cells
in the same way as the IL-6/sIL-6-R complex [14]. How-
ever, its activity is highly enhanced (100-1000 fold) and
the time of action is extended, which is probably due to its
prolonged half-life in blood plasma [15].
Recombinant vaccinia virus strains (rVACV) not only
feature pronounced oncolytic activity, but also serve as
efficient vehicles for delivery and expression of proteins in
vivo. The vaccinia virus vector system has the ability to
stably integrate over 25,000 base pairs of foreign DNA
into the viral genome and is further characterized by its
cytoplasm-restricted gene expression [16]. In rVACV
mediated oncolytic therapy, this can be used to insert
diagnostic or therapeutic genes, including fluorescent pro-
teins and luciferases [17], anti-angiogenic agents [18], or
immunostimulatory cytokines such as GM-CSF [19].
In this study, we constructed the hyper-IL-6-encoding
VACV strain GLV-1h90, which was derived from the pre-
viously described strain GLV-1h68 [20]. After systemic
delivery, GLV-1h90 was capable of infecting and replicat-
ing in established DU-145 prostate xenograft tumors, lead-
ing to overexpression of hyper-IL-6 which in turn is
secreted into the blood circulation. We used this model to
analyze the effects of IL-6 that are exclusively transduced
via the IL-6 trans-signaling pathway in combination with
the oncolytic activity of the vaccinia virus, which included
gain in body weight, levels of thrombocytosis and acceler-
ated epidermal barrier repair.
We further report on a possible medical application for
GLV-1h90. Recently, our group demonstrated that the
combination of viral- and chemotherapy with a number of
different chemotherapeutic agents (e.g. cisplatin or gemci-
tabine) improved the oncolytic activity of the recombinant
vaccinia virus GLV-1h68 [21]. Unfortunately, chemothera-
pies often implicate a wide range of side effects especially
due to non-specific involvement of all rapidly proliferating
cells. One of the most common side effects is myelosup-
pression, which includes a decreased production of throm-
bocytes [22]. Chemotherapy-induced thrombocytopenia is
a significant safety concern due to the increased risk of
bleeding and can delay scheduled treatment [23]. For this
reason, we used the hyper-IL-6-encoding VACV strain
GLV-1h90 in combination therapy with the chemothera-
peutic agent mitomycin C. This approach improves
therapeutic outcomes and reduces negative side effects
such as thrombocytopenia.
Materials and methods
Virus and cell culture
Androgen-insensitive DU-145 human prostatic cancer
cells (authenticated by nonaplex PCR in 2011 [24]) were
cultured in MEM containing 1% glutamaxx, 1% NEAA,
1% sodium pyruvate, 1,5 g/L sodium bicarbonate, 1%
100 × penicillin (10000 units/ml)/streptomycin (10 mg/
mL) solution and 10% fetal bovine serum (FBS) (Invitro-
gen GmbH, Karlsruhe, Germany).
African green monkey kidney fibroblasts (CV-1)
(ATCC-No. CCL-70) were maintained in Dulbecco’s mod-
ified Eagle’s medium (DMEM) supplemented with 1%
100 × penicillin (10000 units/mL)/streptomycin (10 mg/
mL) solution and 10% FBS at 37°C under 5% CO2.
GLV-1h68 was derived from the vaccinia virus strain
LIVP as described previously [20]. In GLV-1h90, the
gusA-containing gene cassette was replaced by hyper-IL-
6-encoding cDNA under control of a vaccinia virus syn-
thetic early promoter (PE).
The plasmid DNA pCDM8-H-IL-6 for the construction
of GLV-1h90 was kindly provided by Dr. Stefan Rose-John
(University of Kiel, Germany), in which a fusion cDNA
encoding a fusion protein of human IL-6 (corresponding
to amino acid residues 29-212) fused to the C-terminus of
human soluble receptor for IL-6 (sIL-6R, corresponding to
amino acid residues 1-323) via a flexible peptide linker.
This fusion cDNA was amplified with primers 5’-
GTCGAC (Sal I) CCACCATGCTGGCCGTCGGC
TGCGC-3’ and 5’-GGTACC (Kpn I) CTAGAGTCGCG
GCCGCGACC-3’ in a PCR, and cloned into the pCR-
Blunt II-TOPO vector (Invitrogen, Carlsbad, CA). The
fusion cDNA was sequencing confirmed, released by Sal I
and Kpn I digestion, and then subcloned into an inter-
mediate vector, placing the cDNA under the control of a
vaccinia synthetic early promoter (PsE). The vaccinia sIL-
6R/IL-6 expression cassette was further subcloned into the
vaccinia hemaglutinin (HA) transfer vector, yielding the
final construct HA-SE-IL-6-1 that was used for recombi-
nation. GLV-1h90 was then generated by insertion of
pSE-sIL-6R/IL-6 into the HA locus of parental strain
GLV-1h68 via in vivo homologous recombination, inter-
rupting the gusA expression cassette at the HA locus of
GLV-1h68. For this, CV-1 cells were infected with GLV-
1h68 at a multiplicity of infection (MOI) of 0.1 for 1 hour,
then transfected with the hyper-IL-6 transfer vector HA-
SE-IL-6-1 using Fugene (Roche, Indianapolis, IN, USA).
Two days post infection (dpi), infected/transfected cells
were harvested and the recombinant viruses were selected
and plaque purified as described previously [25]. The gen-
otype of hyper-IL-6 expressing GLV-1h90 was verified by
PCR and sequencing. Also, the lack of expression of
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b-glucuronidase was confirmed by staining with 5-bromo-
4-chloro-3-indolyl-b-D-glucuronic acid (X-GlcA; Research
Product International, Mt. Prospect, IL, USA).
Protein isolation and detection
At 2, 4, 8, 12, 24, 48, or 72 hours post-infection (hpi), DU-
145 cells were harvested and lysed in RIPA buffer (25
mmol/L Tris-HCl pH 7.6, 150 mmol/L NaCl, 1% NP-40,
1% sodium deoxycholate, 0.1% SDS) supplemented with
proteinase inhibitor cocktail (Roche, Penzberg, Germany).
The cell lysates were separated on a 10% SDS-PAGE, and
proteins were transferred onto a nitrocellulose membrane
(Whatman GmbH, Dassel, Germany). The membrane was
then incubated with anti-beta actin mouse monoclonal
antibody (Abcam, Cambridge, UK), anti-beta galactosidase
rabbit polyclonal antibody (Molecular Probes, Leiden,
Netherlands), anti-GFP rabbit polyclonal antibody (Santa
Cruz, Heidelberg, Germany), or anti-human IL-6 rat
polyclonal antibody (BioLegend, San Diego, US) and
detected using horseradish peroxidase (HRP) labeled sec-
ondary antibodies: anti-mouse (Abcam, Cambridge, UK),
anti-rabbit (Abcam, Cambridge, UK) or anti-rat (Sigma-
Aldrich, Taufkirchen, Germany), followed by enhanced
chemiluminescence.
For the analysis of (Phospho-) STAT3 expression in DU-
145 cells, the cells were incubated with sterile filtered (0.1
μm pore size) supernatants of mock-, GLV-1h68- or GLV-
1h90-infected (MOI of 1.0 for 24 hours) DU-145 cells.
Oncostatin M (Biomol GmbH, Hamburg, Germany),
which also activates the JAK/STAT signaling cascade [26],
was used as a positive control, while gp130/Fc chimera
(R&D Systems, Minneapolis, MN, USA) were added into
the supernatant of GLV-1h90-infected cells to prevent
hyper-IL-6 from binding to the endogenous cellular gp130
receptors. Fifteen minutes later, cell lysates were prepared
as described before, separated with a 10% SDS-PAGE and
proteins were transferred onto a nitrocellulose transfer
membrane. The membrane was then incubated with anti-
STAT3 rabbit polyclonal antibody (Cell Signaling Tech-
nology, Danvers, MA) or anti-phospho-STAT3 rabbit
polyclonal antibody (Cell Signaling Technology, Danvers,
MA).
Quantitative IL-6 specific enzyme-linked immunosor-
bent assay (ELISA) was performed according to the manu-
facturer’s protocols (R&D systems, Minneapolis, MN).
DU-145 cell lysates and supernatants as well as tumor
lysates and sera were analyzed at different time points.
Absorbance was measured at 450 nm using a plate-reading
spectrophotometer (SunriseTM, TECAN Group, Männe-
dorf, Germany).
Histology and fluorescent microscopy
For the microscopic analysis of (Phospho-) STAT3
expression and distribution, DU-145 cells were seeded
on coverslips and incubated with sterile filtered (0.1 μm
pore size) supernatant of mock-, GLV-1h68- or GLV-
1h90-infected (MOI of 1.0 for 24 hours) DU-145 cells.
Fifteen minutes later cells were fixed using 4% parafor-
maldehyde, washed in PBS and stained using anti-
STAT3 rabbit polyclonal antibody (Cell Signaling Tech-
nology, Danvers, MA) or anti-phospho-STAT3 rabbit
polyclonal antibody (Cell Signaling Technology, Dan-
vers, MA) and Hoechst 33342 (Sigma-Aldrich, Tauf-
kirchen, Germany). Microscopy was performed using a
fluorescence microscope (Axiovert 200 M, Zeiss, Ober-
kochen, Germany) equipped with an AxioCam MR cam-
era and the Axiovision 4.5 aquisition software. Digital
images (1388 × 1040 pixel 16-bit grayscale images) were
processed with Photoshop 7.0 (Adobe Systems, USA)
and merged to yield pseudo-coloured pictures.
Histology and fluorescence microscopy of tumor sec-
tions were performed as described previously [27]. Tissue
sections were stained using anti-human IL-6 rabbit poly-
clonal antibody (BioLegend, San Diego, US) and Hoechst
33342 (Sigma-Aldrich, Taufkirchen, Germany), respec-
tively. After several rinses in PBS, tissue sections were
mounted in Mowiol 4-88 (Sigma-Aldrich, Taufkirchen,
Germany).
Tumor specimens were examined with the stereo-fluor-
escence microscope (MZ16 FA, Leica, Heerbrugg, Switzer-
land) equipped with a digital CCD camera (DC500, Leica)
and the Leica IM1000 4.0 acquisition software. Digital
images (1300 × 1030 pixel color images) were processed
with Photoshop 7.0 (Adobe Systems, USA) and merged to
overlay pictures.
For analysis of megakarypoiesis, semi-thin sections of
the bone marrow were prepared. First femurs of mice
were cut in ~0.5 cm pieces and fixed overnight at 4°C with
0.1 M sodium cacodylate (pH 7.2) (Roth, Karlsruhe, Ger-
many) containing 2.5% glutaraldehyde (AppliChem, Darm-
stadt, Germany) and 2% formaldehyde (Sigma-Aldrich,
Taufkirchen, Germany). The bone was removed with for-
ceps before the remaining bone marrow was washed with
50 mM sodium cacodylate (pH 7.2) and subsequently
fixed for 2 hours at 4°C with 2% osmium tetroxide (Roth,
Karlsruhe, Germany) in 50 mM sodium cacodylate (pH
7.2). Samples were washed with distilled water and stained
overnight with 0.5% aqueous uranyl acetate (Merck,
Darmstadt, Germany), dehydrated with ethanol, and
embedded in Epon 812 (Serva, Heidelberg, Germany).
Two-hundred nm semi-thin sections were stained using
1% methylene blue (Merck, Darmstadt, Germany) in 1%
sodium borate (Sigma-Aldrich, Taufkirchen, Germany)
containing 1% Azure II (Merck, Darmstadt, Germany). For
quantification of megakaryocytes 5-8 bone marrow sec-
tions from different layers of each sample (n = 4) were
examined with an Axiovert 200 M microscope (Zeiss,
Oberkochen, Germany) equipped with an AxioCam MRc
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5 camera and the Axiovision 4.5 aquisition software. Small
(~ 30 μm diameter) and large (~ 60 μm diameter) mega-
karyocytes were counted in randomly selected areas.
Animal studies
DU-145 xenograft tumors were developed in 6-to-8-
week-old female nude mice (NCI:Hsd:Athymic Nude-
Foxn1nu, Harlan, Borchem, Germany and Indianapolis,
USA) by implanting 5 × 106 DU-145 cells subcutaneously
in the right hind flank. Fourteen days after tumor cell
implantation, groups of five mice were injected with a
single intravenous (i.v.) dose of PBS, or 5 × 106 plaque
forming units (pfu) of GLV-1h68 or GLV-1h90 in 100 μL
of PBS. Weights of the mice, number of tail lesions as
well as tumor growth, in two dimensions using a digital
caliper, were recorded twice a week. Tumor volume was
calculated as ([length × width2] × 0.52) and reported in
mm3. Concentration of blood platelets was counted 0, 5,
8, 11, 14, 16, 18, 21 and 25 dpi. All animal experiments
were carried out in accordance with protocols approved
by the Institutional Animal Care and Use Committee
(IACUC) of Explora Biolabs (San Diego, USA, protocol
number EB08-003) or the government of Unterfranken
(Würzburg, Germany, protocol number AZ 55.2-
2531.01-17/08).
Tumor lysates
Tumors were collected 2, 5, 9 and 14 dpi, weighed,
homogenized and added to 2x volume of lysis buffer (50
mM Tris-HCl with 2 mM EDTA, pH 7.4) supplemented
with 2 mM phenylmethylsulfonyl fluoride and proteinase
inhibitor cocktail (Roche Diagnostics GmbH, Penzberg,
Germany). Samples were homogenized using a gentle
MACS dissociator (Miltenyi Biotec) and centrifuged for
15 minutes (13000 g, 4°C).
Platelet counting
Peripheral blood samples were obtained by retro-orbital
plexus puncture using 20 μl heparinized capillary tubes
(Hecht assistent, Sondheim, Germany). Mean platelet
numbers were measured in 50 μL whole blood diluted
with 50 μL ACD buffer (12 mM citric acid, 15 mM
sodium citrate, 25 mM D-glucose) with a Sysmex KX-21
automatic micro-cell counter (Sysmex GmbH, Norder-
stedt, Germany).
Combination therapy with mitomycin C
DU-145 tumor bearing mice with an average tumor
volume of 250 mm3 were divided into 3 groups (n = 10).
One group was i.v. injected with a single dose of PBS, the
second and third group with 5 × 106 pfu’s of GLV-1h68 or
GLV-1h90 in 100 μL of PBS. For combination therapy
each group was subdivided into two groups which were
injected with PBS or treated with i.v. injections of
mitomycin C (Medac GmbH, Wedel, Germany) at 4 mg/
kg/day on day 4 after PBS/virus injection and 3 mg/kg/day
on day 5 after PBS/virus injection. Tumor volume, number
of tail lesions as well as number of blood platelets was
recorded over a time period of 25 dpi.
Statistical analysis
A two-tailed Student’s t test was used for statistical ana-
lysis. P values of ≤ 0.05 were considered statistically
significant
Results
Recombinant gene expression in GLV-1h68- or GLV-1h90-
infected DU-145 tumor cells
Expression of the non-viral genes in the recombinant
vaccinia virus strains used in this study was tested in the
human prostatic cancer cell line DU-145. The cells were
infected with the previously described GLV-1h68 [20] or
the hyper-IL-6-encoding GLV-1h90 (Figure 1A).
Protein samples were obtained from infected DU-145
cells at different time points after infection with GLV-
1h68 or GLV-1h90 at an MOI of 0.5. The expression of
Ruc-GFP and beta-galactosidase was observed in cell
lysates upon infection with either rVACV strains starting
at 12 hpi. Concurrently, an increased amount of hyper-
IL-6 was detectable in GLV-1h90-infected cells in con-
trast to GLV-1h68-infected cells, where only thin bands
were observed indicating endogenously produced IL-6
(Figure 1B).
Since hyper-IL-6 must be secreted in order to bind the
extracellular domain of gp130, the supernatant of infected
cells was also analyzed for the presence of the fusion pro-
tein. Here, the secreted designer cytokine was detectable
also at 12 hpi and the hyper-IL-6 concentration increased
during the infection. This indicated active secretion of
hyper-IL-6 by the infected tumor cells. At later stages,
starting from 48 hpi, beta-actin was detectable in cell
supernatants of GLV-1h68- or GLV-1h90-infected cells,
indicating virus-mediated cell lysis (Figure 1B).
Increasing amounts of hyper-IL-6 in the supernatant of
GLV-1h90-infected cells could also be confirmed using an
IL-6-specific ELISA (Figure 1C) reaching a maximum of
about 130 ng/mL at 72 hpi. On the other hand, no hyper-
IL-6 was detectable in cell lysates or supernatants of GLV-
1h68 or uninfected DU-145 cells (data not shown).
Vaccinia virus-mediated hyper-IL-6 expression activates
the JAK/STAT signaling pathway
IL-6 activates the JAK/STAT signaling pathway and
leads to phosphorylation of Tyr-705 of the STAT3 pro-
tein [15]. Upon phosphorylation, STAT3 translocates
into the nucleus ultimately leading to the expression of
target genes involved in differentiation, survival, apopto-
sis and proliferation (reviewed in [28]).
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Figure 1 Vaccinia virus strains and recombinant protein expression. (A) Constructs of the recombinant vaccinia virus strains GLV-1h68 and
GLV-1h90 which were derived from the wild-type Lister strain. The viral genes encoding for F14.5L, thymidine kinase (TK) and hemaglutinin (HA)
were interrupted by the foreign gene expression cassettes encoding for a Renilla-luciferase-GFP (Ruc-GFP) fusion protein, beta-galactosidase
(lacZ), beta-glucuronidase (gusA) and hyper-IL-6, respectively. (B) Infection of DU-145 cells led to expression of the marker genes as visualized by
Western blot analysis of cell lysates and supernatants of infected cells at 2, 4, 8, 12, 24, 48, and 72 hpi. Mock-infected cells (-) served as negative
control. (C) Quantitative (ELISA) measurements of (hyper-) IL-6 in cell lysates and supernatants of GLV-1h90-infected DU-145 cells.
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To analyze the biological activity of GLV-1h90-
encoded hyper-IL-6, the phosphorylation status of
STAT3 and its translocation into the cell nucleus in
DU-145 cells was determined after incubation with the
supernatant of GLV-1h90-infected cells. DU-145 cells
were treated with supernatants from mock-, GLV-1h68-
and GLV-1h90-infected cells, respectively, and protein
samples were harvested after 15 minutes. Oncostatin M,
which also activates the JAK/STAT signal cascade [26],
was used as a positive control, while gp130/Fc chimera
was added in excess in supernatants of GLV-1h90-
infected cells to prevent hyper-IL-6 from binding to the
endogenous cellular gp130 receptors.
As shown in Figure 2A STAT3 was exclusively phos-
phorylated in DU-145 cells treated with oncostatin M
and the supernatant of GLV-1h90-infected cells (hyper-
IL-6). The STAT3 tyrosin 705 phosphorylation induced
by hyper-IL-6 could be blocked by addition of the
gp130/Fc chimera, showing the specificity of hyper-IL-6
to gp130. Total STAT3 expression was not altered (Fig-
ure 2A lower panels) and used as loading control.
Immunofluorescence analysis of STAT3 (Figure 2B)
and Phospho-STAT3 (Figure 2C) confirmed these
results and showed activation of the JAK/STAT path-
way. The anti-STAT3 antibody detected STAT3 regard-
less of its phosphorylation state. Therefore, it was
possible to directly track the translocation of (Phospho-)
STAT3 into the cells’ nucleus of DU-145 cells incubated
with the conditioned media of GLV-1h90-infected cells
or oncostatin M. The (Phospho-) STAT3 protein was
detected exclusively in the nucleus in DU-145 cells trea-
ted with the supernatant of GLV-1h90-infected cells or
oncostatin M, whereas in the remaining experimental
groups the STAT3 protein could be detected both in
the cytoplasm and in the nucleus. Staining for Phospho-
STAT3 confirmed this observation as Phospho-STAT3
could only be detected in the GLV-1h90 and the oncos-
tatin M groups and was exclusively located in the cell
nucleus.
Taken together, virally encoded hyper-IL-6 was effi-
ciently and functionally secreted from infected tumor
cells. In addition, these results clearly showed specific
activation of the JAK/STAT pathway by vaccinia virus-
encoded hyper-IL-6 in human prostatic cancer cells.
Hyper-IL-6 expression could be detected both in tumors
and in blood serum of GLV-1h90-injected mice
Similar to the observations made for GLV-1h68 [20],
systemic administration of GLV-1h90 into tumor-bear-
ing mice resulted in specific replication of vaccinia virus
in tumor tissue (data not shown).
To demonstrate hyper-IL-6 expression in GLV-1h90-
colonized tumors, tumors from PBS-, GLV-1h68-, or
GLV-1h90-injected mice were isolated 2, 5, 9 and 14 dpi
and tumor tissue homogenates were prepared. Quantita-
tive protein analysis revealed high amounts of hyper-
IL-6 in GLV-1h90-colonized tumors with a maximum
concentration of about 7900 ng/g tissue at 9 dpi (Fig-
ure 3A). At this time point the concentration of IL-6
in control tumors of PBS- or GLV-1h68-injected mice
was around 345-fold lower (on average 22,85 ng/g in
PBS- and 23,45 ng/g in GLV-1h68-injected mice).
Of special interest was the presence of hyper-IL-6 in
blood serum samples of GLV-1h90-injected mice (Figure
3B), which is essential for its ability to induce signal
transduction pathways outside the tumor. Hyper-IL-6
was actively secreted into the blood circulation as indi-
cated by the same detection pattern over infection time
in both the tumor and the blood (Figure 3AB). The
hyper-IL-6 concentration in the blood serum also
reached its maximum 9 dpi and was ~ 800 pg/mL. In
PBS-injected mice the IL-6 concentration was ~ 130-
fold lower and ~ 65-fold lower in GLV-1h68-injected
mice (on average 6 pg/mL and 12 pg/mL in PBS- and
GLV-1h68-injected mice, respectively) (Figure 3B) com-
pared to GLV-1h90-treated animals.
Also, fluorescence microscopy of tumor sections 11
dpi confirmed the expression of hyper-IL-6 (Figure 3C).
While GFP could be observed in GLV-1h68- and GLV-
1h90-infected tumors, high amounts of hyper-IL-6 could
only be detected in GLV-1h90-colonized tumors. As
expected, the distribution of the fusion protein corre-
lated with the area of GFP expression, since both pro-
teins were encoded by GLV-1h90.
Effects of GLV-1h90 in a DU-145 xenograft mouse model
For analysis of oncolytic effects in live animals, DU-145
tumor-bearing mice were injected i.v. with either PBS or
5 × 106 pfu of GLV-1h68 and the hyper-IL-6-encoding
GLV-1h90, respectively. Systemic administration of
either viral constructs led to significant tumor regression
starting 18 dpi compared to PBS injection. The compar-
ison of both viral constructs revealed no significant dif-
ferences in the inhibition of tumor growth except 22 dpi
when GLV-1h90-colonized tumors were significantly
smaller compared to those colonized with GLV-1h68
(Figure 4A), while viral titers in tumor tissue showed no
relevant difference between both constructs (data not
shown).
Besides the slightly increased oncolytic activity, GLV-
1h90 revealed important benefits over GLV-1h68
mediated by the overexpression of the encoded designer
cytokine hyper-IL-6. One of those advantages compared
to GLV-1h68 concerned the healthiness of the mice
during viral therapy. The health status of the mice was
determined by measurement of the net body weight
(body weight without tumor weight). As shown in Fig-
ure 4B, GLV-1h90 injection led to a significant increase
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Figure 2 Hyper-IL-6 dependent activation of the JAK/STAT signaling pathway. (A) Western blot analysis of phosphorylated STAT3 (P-STAT3)
and unphosphorylated STAT3 in DU-145 cells after co-incubation with sterile filtered supernatants of mock- (-), GLV-1h68- (68) or GLV-1h90- (90)
infected cells. Oncostatin M (OSM) served as positive control and gp130/Fc chimera was added in excess to the supernatants of GLV-1h90-
infected cells (90/gp130) to show specific activation via cellular gp130. Hyper-IL-6 and oncostatin M dependent migration of STAT3 into the
nuclei (B) and phosphorylation (C) of STAT3 in DU-145 cells were proven by immunofluorescent microscopy. Overlay images (large picture)
resulting from cells stained for (phosphorylated) STAT3 (red), and Hoechst 33342 stained nuclei (blue) were depicted. Scale bars indicate 8.6 μm.
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Figure 3 Detection of hyper-IL-6 in tumors and blood serum samples of GLV-1h90-injected mice. Quantification (ELISA) of hyper-IL-6 in
tumor lysates (A) and blood serum samples (B) of mock-, 5 × 106 pfu GLV-1h68- or GLV-1h90-injected mice at 2, 5, 9 and 14 dpi. (C) Whole
tumor cross sections (100 μm) 11 days post injection of 5 × 106 pfu GLV-1h68 or GLV-1h90 were stained with anti-IL-6 antibody (red) to confirm
hyper-IL-6 expression only in GLV-1h90-infected tumors. Viral infection was indicated by GFP (green), and nuclei were stained with Hoechst
33342 (blue). Scale bars indicate 5 mm.
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Figure 4 Effects of GLV-1h90 in a DU-145 xenograft mouse model. (A) Tumor measurements of DU-145 tumor bearing mice injected i.v.
with PBS, 5 × 106 pfu GLV-1h68 or GLV-1h90 at 0, 4, 7, 11, 15, 18, 22, 25 and 31 dpi. (B) Net body weight change at the same time points. (C)
Quantification of blood platelets in whole blood samples obtained by retro-orbital plexus puncture of PBS-, GLV-1h68- or GLV-1h90-injected
mice. (D) Amount of tail lesions was counted over the whole experiment duration. Data represent average plus standard deviation for each
group (n = 5). * indicates p ≤ 0.05; ** indicates p ≤ 0.01; *** indicates p ≤ 0.005. (E) Quantification of megakaryocytes of different maturation
stages 7 dpi in semi-this sections of the bone marrow. Data represent average of 2 analyzed areas (20 × 22 cm) per section with 5-8 sections
per sample (n = 4) plus standard deviation. * indicates p ≤ 0.05; ** indicates p ≤ 0.01; *** indicates p ≤ 0.005. (F) Examples for the analyzed
bone marrow sections. S indicates small megakaryocytes; L indicates large megakaryocytes in advanced maturation phases; scale bars indicate
100 μm.
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in the net body weight starting 15 dpi compared to
GLV-1h68 or PBS injection. However, it was not investi-
gated whether the increased weight could be attributed
to tissue or fluid, althogh no obvious fluid retentions
were detected. Furthermore, mice injected with the
hyper-IL-6-encoding VACV seemed to be more active,
which indicated (together with the increased weight) an
improved health status of the mice.
Another indication for the health status of the mice
was the number and fate of tail lesions. Mice injected
with either viral construct developed tail lesions at the
site of virus injection starting 4 dpi which began
increasing over time. Seven dpi, the number of GLV-
1h90-induced tail lesions were reduced markedly and by
31 dpi a significant difference was observed compared
to mice injected with GLV-1h68 (on average 0.4 in
GLV-1h90- and 3.2 tail lesions in GLV-1h68-injected
mice) (Figure 4C and Additional File 1 Figure S1). The
observed accelerated barrier repair of tail lesions can be
the result of direct or indirect antiviral activity mediated
by IL-6 [29], keeping in mind that tail lesions are not
only wounds which occur after tissue injury, but rather
are associated with viral infection.
Barrier repair is a tightly regulated process in which
blood platelets play an important role. Based on this, we
analyzed whether overexpression of hyper-IL-6 leads to
elevated levels of blood platelets in GLV-1h90-injected
mice. Figure 4D shows that, in contrast to PBS or GLV-
1h68, GLV-1h90 injection into DU-145 tumor-bearing
mice significantly increased the number of platelets in
the blood first detected 8 dpi and reached its maximum
around 11 dpi which was about 2-fold increased com-
pared to the other experimental groups. Subsequently,
platelet concentration decreased and was nearly at base-
line at 25 dpi. The number of neutrophils, lymphocytes
and monocytes and red blood cells as well as hemoglo-
bin levels showed normal levels with no differences
between GLV-1h90-injected mice and the control
groups (data not shown).
To further characterize if the increased platelet pro-
duction was due to a hyper-IL-6-dependent stimulation
of megakaryopoiesis in the bone marrow, megakaryo-
cytes of different maturation phases were quantified in
semi-thin cuts of the bone marrow. After injection of
GLV-1h90, significant higher numbers of megakaryo-
cytes could be detected in an advanced maturation
phase (indicated by bigger size due to polyploidy) com-
pared to GLV-1h68- or PBS-injected mice. At the same
time, significant lower numbers of megakaryocytes
could be visualized in early stages of megakaryopoiesis
with smaller size in GLV-1h90-treated when compared
to PBS-treated mice. The GLV-1h68-group showed
lower megakaryocyte numbers in both analyzed matura-
tion phases (Figure 4EF).
Combination therapy with mitomycin C
Recently, we and others have demonstrated that the
combination of oncolytic virotherapy with chemother-
apy could lead to interactions that ultimately result in
enhanced therapeutic effects [21,30]. On the other
hand, chemotherapy is often associated with negative
side effects, with thrombocytopenia one of the most fre-
quently observed in cancer patients [31]. Consequently,
we wanted to test the use of recombinant vaccinia
virus-encoding hyper-IL-6 (GLV-1h90) instead of the
parent virus GLV-1h68 in combination with the che-
motherapeutic agent mitomycin C to improve not only
the oncolytic effect but also the well being of the mice
based on the observed effects of GLV-1h90. Mitomycin
C is known to cause severe thrombocytopenia [32],
which, as observed in first experiments, occurs around
7 days post chemotherapeutic treatment (data not
shown). Therefore, as can be seen in the injection sche-
dule (Figure 5A), we included mitomycin C injections at
4 and 5 days after initialization of virus treatment,
assuming that GLV-1h90-induced production of throm-
bocytes could counteract chemotherapy-induced
thrombocytopenia.
Combination therapy with mitomycin C and the onco-
lytic vaccinia virus strains led to a significantly improved
DU-145 tumor regression compared to the respective
monotherapies (Figure 5B). As early as 15 days post
virus injection significant differences were observed
between the groups injected with rVACV alone and
those receiving the combination therapy regime. At that
time, the tumor volume was already reduced to its initial
dimension. In case of the rVACV monotherapy, it
required ~ 22 days for the GLV-1h90- and 25 days for
the GLV-1h68-injected group to reach the same tumor
volume. Mitomycin C injection alone only led to tumor
stagnation and therapeutic effects did not reach statisti-
cal significance when compared to PBS-treated controls.
As already observed in our previous experiment,
tumor regression in GLV-1h90-injected animals was
more pronounced compared to those injected with
GLV-1h68, but again did not reach statistical signifi-
cance. The same held true for the combination therapy
with mitomycin C; although combination therapy was
significantly better than the respective viral therapy
alone, no significant differences in terms of tumor
regression were observed between the GLV-1h68 and
GLV-1h90 combination therapy groups.
However, analysis of the number of tail lesions
revealed significant variations (Figure 5C and Additional
File 2 Figure S2), indicating that combination of the
viral constructs with the chemotherapeutic agent mito-
mycin C did not have any effects on wound healing.
Approximately one week after virus injection the num-
ber of tail lesions decreased in GLV-1h90-injected mice
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Figure 5 Combination therapy of GLV-1h90 with mitomycin C. (A) Injection schedule. (B) Tumor growth curve of DU-145 tumor bearing
mice injected either with PBS, 5 × 106 pfu GLV-1h68 or GLV-1h90 alone or in combination with mitomycin C. Tumor volume was measured at
0, 4, 7, 11, 15, 18, 22 and 25 dpi. (C) Amount of tail lesions was counted starting 4 dpi, the time point when they occurred. (D) Quantification of
blood platelets in whole blood samples of mice injected with PBS alone as well as of mice injected with PBS, GLV-1h68 or GLV-1h90 each in
combination with mitomycin C at 8, 11, 14, 18, 21 and 25 dpi. The lower panel shows duration of thrombocytopenia in mice treated with
mitomycin C. Thrombocytopenia is defined by a significantly decreased platelet number in relation to PBS-injected mice. Data in B, C and D
represent average plus standard deviation for each group (n = 5). * indicates p ≤ 0.05; ** indicates p ≤ 0.01; *** indicates p ≤ 0.005; ns not
significant.
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while remaining stable or slightly increased in the GLV-
1h68-injected groups.
Noteable was the finding that GLV-1h90 significantly
reduced the time interval during which the mice suffered
from thrombocytopenia (Figure 5D). Compared to PBS-
injected mice, the treatment with mitomycin C resulted
in significantly reduced platelet numbers for at least two
weeks (from day 11 to at least day 25) in the PBS plus
mitomycin C as well as in the GLV-1h68 plus mitomycin
C groups. In contrast, combination of GLV-1h90 and
mitomycin C led to a delayed occurrence of thrombocy-
topenia, as well as acceleration of the recovery process.
Consequently, reduced platelet numbers were detectable
for less than one week in the GLV-1h90 plus mitomycin
C-injected group (14 to 18 dpi).
Taken together, functionally expressed hyper-IL-6
through i.v. delivered vaccinia virus optimized the combi-
nation therapy of the oncolytic virus GLV-1h90 and the
chemotherapeutic agent mitomycin C. Besides the
improved oncolytic effect, which also occurred with the
parental strain GLV-1h68, GLV-1h90 was further able to
significantly reduce thrombocytopenia, a negative side
effect caused by the chemotherapeutic agent.
Discussion
Among the currently investigated cancer therapies, the use
of oncolytic vaccinia virus strains appear to be one of the
most promising against a wide range of solid tumors [33].
While initial clinical trials using engineered oncolytic vac-
cinia virus strains have already been carried out [19,34],
current research focuses on enhancing the already promis-
ing therapeutic effects of these viruses. This includes
virus-mediated expression of immune-modulatory mole-
cules [35,36], and combination with alternative therapies,
such as prodrug therapy [37,38], radiation (Advani et al.,
submitted), or conventional chemotherapy [21,36]. The
latter have been described to be very effective, but still suf-
fer from the disadvantage of severe side effects.
Here, the hyper-IL-6-encoding rVACV strain GLV-
1h90 was used to reduce the side effects resulting from
the chemotherapeutic agent mitomycin C. This che-
motherapeutic agent, as well as most other agents, is
known to cause severe thrombocytopenia in mice as well
as in human patients [32,39]. Interleukin-6 is a cytokine
with multifunctional actions including regulation of
immune responses [40,41], induction of acute-phase
reactant release from hepatocytes [42] and enhancement
of proliferation of hematopoietic progenitors [3]. In parti-
cular, the IL-6-promoted megakaryocyte maturation in
the absence of other added growth factors, which leads to
elevated platelet production [43,44] is an important focus
when contemplating its implications on chemotherapy-
induced thrombocytopenia.
Systemic administration of GLV-1h90 into DU-145
tumor-bearing mice led to significant tumor regression
compared to mock-injected mice. This anti-tumor effect
in this tumor model, as well as others, has been shown to
be similar to that achieved by treatment with GLV-1h68
(data not shown). This result suggests that hyper-IL-6
itself has no significant direct anti-tumor activity or that
virus-mediated oncolysis is, in the model systems tested,
the most prominent factor responsible for tumor destruc-
tion, which may therefore mask potential cytokine effects.
However, our results clearly indicated that hyper-IL-6
maintained its biological activity when encoded by the
oncolytic vaccinia virus strain. Large amounts of the cyto-
kine were produced in and secreted from infected tumor
cells in cell culture as well as in live animals. Secretion is
crucial since the presence of hyper-IL-6 in blood is needed
for the designer-cytokine to act outside the tumor tissue
such as on megakaryocytes in the bone marrow [43,44] or
on skin keratinocytes [45].
Hyper-IL-6-dependent activation of the JAK/STAT
pathway was demonstrated on a molecular level by
Western blot analysis and immunohistochemistry in cell
culture. Furthermore, functionality of hyper-IL-6 in
tumor-bearing mice resulted in elevated acute phase pro-
teins (data not shown) as well as in accelerated epithelial
barrier repair of tail lesions. IL-6 is known to affect multi-
ple processes which are related to wound healing includ-
ing attraction of neutrophils and their adhesion to dermal
fibroblasts [46], recruitment of monocyte/macrophages
responsible for clearance of debris and the provision of
growth and angiogenic factors [47] and stimulation of ker-
atinocyte proliferation which accelerates re-epithelializa-
tion after injury [45,48]. Furthermore, the observed
accelerated barrier repair of tail lesions can be the result of
direct or indirect antiviral activity mediated by IL-6 [29],
keeping in mind that tail lesions are not only wounds
which occur after tissue injury, but rather are associated
with viral infection. Thus, future experiments are planned
to investigate which processes are crucial in the here
observed improved wound healing.
In addition, elevated platelet numbers in the blood cir-
culation of mice injected with the hyper-IL-6 virus may
also contribute to the accelerated healing of tail lesions
[49]. In the blood of GLV-1h90-injected mice the platelet
concentration increased after 5 dpi and reached its maxi-
mum around 11 dpi after which their concentration
declined. A similar peak, about 2-3 days earlier, was also
observed for the hyper-IL-6 concentration in the tumors
as well as in the sera of GLV-1h90-injected mice. This
suggests that, as a result of the intratumoral overexpres-
sion, hyper-IL-6 ends up in the blood circulation and can
reach the bone marrow, where the designer cytokine can
stimulate megakaryopoiesis. This process in turn leads to
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increased production of platelets, which could then be
found in the blood several days later [43]. This hypothesis
could be proven by quantification of different maturation
phases of megakaryocytes in semi-thin cuts of the bone
marrow. Besides thrombopoietin (TPO), the main regula-
tor of megakaryopoiesis, many pro-inflammatory cyto-
kines are known to stimulate, either alone or in
conjunction with TPO, platelet production during mega-
karyopoiesis. While interleukin-3 is essential in early
steps of megakaryopoiesis, IL-6 is postulated to be mainly
involved in a process called endomitosis, which include
megakaryocyte proliferation, cell growth as well as for-
mation of polyploidy at the latest phase of megakaryopoi-
esis. The observation that, compared to both control
groups, 7 dpi significant higher numbers of megakaryo-
cytes in advanced maturation phases could be detected in
bone marrow sections of GLV-1h90-injected mice con-
firms the assumption that hyper-IL-6 was able to stimu-
late megakaryopoiesis which in turn leads to elevated
platelet numbers 3-4 days later. The platelet decrease
might reflect the therapeutic effects caused by the virus,
reducing the amount of viable (hyper-IL-6 producing)
tumor cells. The results also illustrate that possible com-
plications associated with the overexpression of cytokines
can be self-limiting due to the destruction of the virus
replication site.
Here, we showed for the first time, that oncolytic
tumor therapy could be optimized through reduction of
therapeutic side effects associated with chemotherapy
such as thrombocytopenia, in mice receiving combina-
tion therapy with mitomycin C by using a hyper-IL-6-
encoding vaccinia virus. The time period that mice
experienced thrombocytopenia was reduced by at least
50% (less than one week compared to at least 2 weeks).
Moreover, the combination of mitomycin C with either
of the oncolytic vaccinia virus strains GLV-1h68 or
GLV-1h90 resulted in significantly enhanced therapeutic
effects.
Taken together, GLV-1h90 resulted in the production
of the functionally active designer-cytokine hyper-IL-6
thereby retaining the oncolytic effects of its parental
strain GLV-1h68. Maybe even more importantly, GLV-
1h90 significantly improved the wellbeing of mice dur-
ing combination therapy with mitomycin C.
For translation into the clinic, future studies on a
higher number of tumor models will have to show if
this also holds true for combinations with other che-
motherapeutic agents, and whether other cytokines such
as IL-2 and IL-11 that are already applied for treatment
of thrombocytopenia in cancer patients receiving che-
motherapy, will be as efficacious or maybe even superior
to hyper-IL-6 in reducing thrombocytopenia and
improving overall wellbeing in combination with oncoly-
tic viral therapy.
Conclusion
We have shown that the oncolytic vaccinia virus strain
GLV-1h90 can be used to functionally express the
designer cytokine hyper-IL-6 in human tumor xeno-
grafts of live mice. Hyper-IL-6 was secreted from the
infected tumor tissue into the circulatory system
enabling it to induce systemic effects. This was used, for
the first time, to improve combination of oncolytic vac-
cinia virus therapy with conventional chemotherapy.
Although this has previously been shown to have
remarkable success in preclinical tumor models, the
virus-mediated expression of the designer cytokine
hyper-IL-6 offered a new approach to significantly
reduce the duration of thrombocytopenia, a serious side
effect of chemotherapy. Therefore, future pre-clinical
studies investigating combination treatment with che-
motherapy would benefit from careful investigation into
the possibility of additional cytokine expression to
reduce chemotherapy-induced side effects before pro-
gression to clinical trials.
Additional material
Additional file 1: Figure S1. Effect of hyper-IL-6 on epithelial barrier
repair of tail lesions. Fluorescence microscopy of tail lesions of DU-145
tumor-bearing mice injected with 5 × 106 pfu GLV-1h68 (left panels) or
GLV-1h90 (right panels), respectively. Viral infection was indicated by GFP
(green). Images were taken at 25 dpi with a stereo-fluorescence
microscope (MZ16 FA, Leica, Heerbrugg, Switzerland) equipped with a
digital CCD camera (DC500, Leica) and the Leica IM1000 4.0 acquisition
software. Digital images (1300 × 1030 pixel color images) were
processed with Photoshop 7.0 (Adobe Systems, USA) and merged to
overlay pictures. Scale bars in the upper panels indicate 5 mm; scale bars
in the lower panels indicate 1 mm.
Additional file 2: Figure S2. Epithelial barrier repair of GLV-1h68- or
GLV-1h90-induced tail lesions in combination therapy with
mitomycin C. Fluorescence microscopy of tail lesions of DU-145 tumor
bearing mice injected either with 5 × 106 pfu GLV-1h68 or GLV-1h90
alone or in each case in combination with mitomycin C at 25 dpi. Viral
infection was indicated by GFP (green). Images were taken with a stereo-
fluorescence microscope (MZ16 FA, Leica, Heerbrugg, Switzerland)
equipped with a digital CCD camera (DC500, Leica) and the Leica IM1000
4.0 acquisition software. Digital images (1300 × 1030 pixel color images)
were processed with Photoshop 7.0 (Adobe Systems, USA) and merged
to overlay pictures. Scale bars indicate 5 mm.
List of abbreviations
dpi: days post infection; ELISA: enzyme-linked immunosorbent assay; FBS:
fetal bovine serum; GFP: Green fluorescent protein; GM-CSF: Granulocyte-
macrophage colony-stimulating factor, hpi: hours post-infection; HA:
hemagluttinin; HRP: horseradish peroxidase; IL: interleukin; IL-6TS: IL-6 trans-
signaling; i.v.: intravenous; mIL-6-R: membrane bound IL-6 receptor; rVACV:
recombinant vaccinia virus strain; sIL-6-R: soluble IL-6 receptor; TK: thymidine
kinase.
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